{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038329","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.726131+00:00","generated_at":"2026-05-17T19:38:31.167990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway","bullets":["Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.","Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.","ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.","First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.","R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038329","json":"https://secwatch.observer/filing/0001628280-25-038329.json","markdown":"https://secwatch.observer/filing/0001628280-25-038329.md","text":"https://secwatch.observer/filing/0001628280-25-038329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/0001628280-25-038329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/vir-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:38:31.167990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}